WO2008021960A2 - Inhibiteurs triazolyle macrocycliques de la sérine protéase de l'hépatite c - Google Patents

Inhibiteurs triazolyle macrocycliques de la sérine protéase de l'hépatite c Download PDF

Info

Publication number
WO2008021960A2
WO2008021960A2 PCT/US2007/075588 US2007075588W WO2008021960A2 WO 2008021960 A2 WO2008021960 A2 WO 2008021960A2 US 2007075588 W US2007075588 W US 2007075588W WO 2008021960 A2 WO2008021960 A2 WO 2008021960A2
Authority
WO
WIPO (PCT)
Prior art keywords
substituted
cycloalkyl
alkenyl
alkyl
heteroaryl
Prior art date
Application number
PCT/US2007/075588
Other languages
English (en)
Other versions
WO2008021960A3 (fr
Inventor
Ying Sun
Deqiang Niu
Yat Sun Or
Zhe Wang
Original Assignee
Enanta Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/835,657 external-priority patent/US7662779B2/en
Application filed by Enanta Pharmaceuticals, Inc. filed Critical Enanta Pharmaceuticals, Inc.
Publication of WO2008021960A2 publication Critical patent/WO2008021960A2/fr
Publication of WO2008021960A3 publication Critical patent/WO2008021960A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N

Definitions

  • the present invention relates to triazolyl macrocyclic hepatitis C virus (HCV) protease inhibitors having antiviral activity against HCV and useful in the treatment of HCV infections. More particularly, the invention relates to triazolyl macrocyclic HCV protease inhibitor compounds, compositions containing such compounds and methods for using the same, as well as processes for making such compounds.
  • HCV hepatitis C virus
  • HCV is the principal cause of non-A, non-B hepatitis and is an increasingly severe public health problem both in the developed and developing world. It is estimated that the virus infects over 200 million people worldwide, surpassing the number of individuals infected with the human immunodeficiency virus (HIV) by nearly five fold. HCV infected patients, due to the high percentage of individuals inflicted with chronic infections, are at an elevated risk of developing cirrhosis of the liver, subsequent hepatocellular carcinoma and terminal liver disease. HCV is the most prevalent cause of hepatocellular cancer and cause of patients requiring liver transplantations in the western world.
  • HIV human immunodeficiency virus
  • anti-HC V therapeutics There are considerable barriers to the development of anti-HC V therapeutics, which include, but are not limited to, the persistence of the virus, the genetic diversity of the virus during replication in the host, the high incident rate of the virus developing drug-resistant mutants, and the lack of reproducible infectious culture systems and small-animal models for HCV replication and pathogenesis.
  • the persistence of the virus the genetic diversity of the virus during replication in the host
  • the high incident rate of the virus developing drug-resistant mutants the lack of reproducible infectious culture systems and small-animal models for HCV replication and pathogenesis.
  • antiviral drugs Only two approved therapies for HCV infection are currently available.
  • the original treatment regimen generally involves a 3-12 month course of intravenous interferon- ⁇ (IFN- ⁇ ), while a new approved second-generation treatment involves co-treatment with IFN- ⁇ and the general antiviral nucleoside mimics like ribavirin. Both of these treatments suffer from interferon related side effects as well as low efficacy against HCV infections. There exists a need for the development of effective antiviral agents for treatment of HCV infection due to the poor tolerability and disappointing efficacy of existing therapies.
  • NS3 hepatitis C non-structural protein-3
  • HCV is a flaviridae type RNA virus.
  • the HCV genome is enveloped and contains a single strand RNA molecule composed of circa 9600 base pairs. It encodes a polypeptide comprised of approximately 3010 amino acids.
  • the HCV polyprotein is processed by viral and host peptidase into 10 discreet peptides which serve a variety of functions. There are three structural proteins, C, El and E2.
  • the P7 protein is of unknown function and is comprised of a highly variable sequence.
  • NS2 is a zinc-dependent metalloproteinase that functions in conjunction with a portion of the NS3 protein.
  • NS3 incorporates two catalytic functions (separate from its association with NS2): a serine protease at the N-terminal end, which requires NS4A as a cofactor, and an ATP-ase-dependent helicase function at the carboxyl terminus.
  • NS4A is a tightly associated but non-covalent cofactor of the serine protease.
  • the NS3-NS4A protease is responsible for cleaving four sites on the viral polyprotein.
  • the NS3-NS4A cleavage is autocatalytic, occurring in cis.
  • the remaining three hydrolyses, NS4A-NS4B, NS4B-NS5A and NS5A-NS5B all occur in trans.
  • NS3 is a serine protease which is structurally classified as a chymotrypsin-like protease. While the NS serine protease possesses proteolytic activity by itself, the HCV protease enzyme is not an efficient enzyme in terms of catalyzing polyprotein cleavage. It has been shown that a central hydrophobic region of the NS4A protein is required for this enhancement. The complex formation of the NS3 protein with NS4A seems necessary to the processing events, enhancing the proteolytic efficacy at all of the sites.
  • a general strategy for the development of antiviral agents is to inactivate virally encoded enzymes, including NS3, that are essential for the replication of the virus.
  • Current efforts directed toward the discovery of NS3 protease inhibitors were reviewed by S. Tan, A. Pause, Y. Shi, N. Sonenberg, Hepatitis C Therapeutics: Current Status and Emerging Strategies, Nature Rev. Drug Discov., 1, 867-881 (2002).
  • Other patent disclosures describing the synthesis of HCV protease inhibitors are: WO 00/59929 (2000); WO 99/07733 (1999); WO 00/09543 (2000); WO 99/50230 (1999); US5861297 (1999); and US2002/0037998 (2002).
  • the present invention relates to triazolyl macrocyclic HCV protease compounds, and including pharmaceutically acceptable salts, esters, or prodrugs thereof which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents.
  • the present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection.
  • the present invention further features pharmaceutical compositions comprising a compound of the present invention (or a pharmaceutically acceptable salt, ester or prodrug thereof) and another anti-HCV agent, such as interferon (e.g., alpha-interferon, beta-interferon, consensus interferon, pegylated interferon, or albumin or other conjugated interferon), ribavirin, amantadine, another HCV protease inhibitor, or an HCV polymerase, helicase or internal ribosome entry site inhibitor.
  • interferon e.g., alpha-interferon, beta-interferon, consensus interferon, pegylated interferon, or albumin or other conjugated interferon
  • ribavirin e.g., amantadine
  • another HCV protease inhibitor e.g., alpha-interferon, beta-interferon, consensus interferon, pegylated interferon, or albumin or other conjugated interferon
  • Ri is selected from the group consisting of:
  • R 2 is independently selected from the group consisting of: (i) aryl; substituted aryl; heteroaryl; substituted heteroaryl; (ii) heterocycloalkyl or substituted heterocycloalkyl; and (iii) -C 1 -C 8 alkyl, -C 2 -Cs alkenyl, or -C 2 -Cs alkynyl each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; substituted -Ci-Cs alkyl, substituted -C 2 -Cs alkenyl, or substituted -C 2 -Cs alkynyl each containing 0, 1, 2, or 3 heteroatoms selected from O, S or N; -C 3 - Ci 2 cycloalkyl, or substituted -C 3 -Ci 2 cycloalkyl; -C 3 -Ci 2 cycloalkenyl, or substituted -C 3 -Ci 2 cycloalkenyl;
  • G is selected from the group consisting Of-NHS(O) 2 -R 3 and - NH(SO 2 )NR 4 R 5 ;
  • R 3 is selected from:
  • R 4 and R 5 are independently selected from:
  • heterocycloalkyl or substituted heterocycloalkyl (iii) heterocycloalkyl or substituted heterocycloalkyl; and (iv) -Ci-C 8 alkyl, -C 2 -C 8 alkenyl, or -C 2 -C 8 alkynyl each containing 0,
  • L is selected from -CH 2 -, -O-, -S-, and -S(O) 2 -;
  • X and Y are independently selected from: (i) hydrogen;
  • R 6 is selected from the group consisting of:
  • a first embodiment of the invention is a compound represented by Formulae I and II as described above, or a pharmaceutically acceptable salt, ester or prodrug thereof, alone or in combination with a pharmaceutically acceptable carrier or excipient.
  • X and Y are independently selected from the group consisting of hydrogen, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, -Ci-Cs alkyl, -C 2 -Cs alkenyl, or -C 2 -Cs alkynyl, substituted -Ci-Cs alkyl, substituted -C 2 -Cs alkenyl, or substituted -C 2 -Cs alkynyl, -C 3 -C 12 cycloalkyl, -C 3 -Ci 2 cycloalkenyl, substituted -C 3 -Ci 2 cycloalkyl, and substituted -C 3 -Ci 2 cycloalkenyl, where each -Ci-Cs alkyl, -C 2 -Cs alkenyl, -C 2 -Cs alkynyl, substituted -Ci-Cs alkyl, substitute
  • A is selected from the group consisting of -C(O)-Ri, - C(O)-O-Ri and -C(O)-NH-Ri, where Ri is selected from aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, -Ci-Cs alkyl, -C 2 -Cs alkenyl, -C 2 -Cs alkynyl, substituted -Ci-Cs alkyl, substituted -C 2 -Cs alkenyl, substituted -C 2 -Cs alkynyl, -C 3 -Ci 2 cycloalkyl, -C 3 -Ci 2 cycloalkenyl, substituted -C 3 -Ci 2 cycloalkyl, or substituted -C 3 -Ci 2 cycloalkenyl.
  • G can be - NH-SO 2 -NR 4 R 5 or -NHSO 2 -R 3 , where R 3 is selected from -Ci-C 8 alkyl, -C 2 -C 8 alkenyl, -C 2 -C 8 alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, -C 3 -Ci 2 cycloalkyl, -C 3 -Ci 2 cycloalkenyl, substituted -C 3 -Ci 2 cycloalkyl, or substituted -C 3 -Ci 2 cycloalkenyl, and R 4 and R 5 are each independently selected from hydrogen, -Ci-C 8 alkyl, -C 2 -C 8 alkenyl, -C 2 - C 8 alkynyl, substituted -Ci-C 8 alkyl, substituted -C 2 -C 8 alkenyl, substituted
  • X and Y are independently selected from the group consisting of hydrogen, aryl, substituted aryl, heteroaryl, and substituted heteroaryl.
  • A is -C(O)-O-Ri or -C(O)-NH-Ri, where Ri is -C r C 8 alkyl, -C 2 -C 8 alkenyl, -C 2 -C 8 alkynyl, substituted -Ci-C 8 alkyl, substituted -C 2 -C 8 alkenyl, substituted -C 2 -C 8 alkynyl, -C 3 -Ci 2 cycloalkyl, -C 3 -Ci 2 cycloalkenyl, substituted - C 3 -Ci 2 cycloalkyl, or substituted -C 3 -Ci 2 cycloalkenyl.
  • G is -NHSO 2 -R 3 , where R 3 is selected from aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, -C 3 -Ci 2 cycloalkyl, -C 3 -Ci 2 cycloalkenyl, substituted -C 3 -Ci 2 cycloalkyl, or substituted -C 3 -Ci 2 cycloalkenyl.
  • X and Y are independently selected from the group consisting of aryl, substituted aryl, heteroaryl, and substituted heteroaryl.
  • A is -C(O)-O-Ri, where Ri is -C 3 -Ci 2 cycloalkyl or substituted -C 3 -Ci 2 cycloalkyl.
  • G is -NHSO 2 -R 3 , where R 3 is selected from -C 3 -Ci 2 cycloalkyl or substituted -C 3 - Ci 2 cycloalkyl.
  • X and Y are independently selected from the group consisting of aryl, substituted aryl, heteroaryl, and substituted heteroaryl.
  • A is - C(O)-NH-Ri, where Ri is -Ci-C 8 alkyl or substituted -Ci-C 8 alkyl.
  • G is -NHSO 2 - R 3 , where R 3 is selected from -C 3 -Ci 2 cycloalkyl or substituted -C 3 -Ci 2 cycloalkyl.
  • X is substituted or unsubstituted aryl (e.g., ),
  • A is selected from the group consisting of -C(O)-Ri, -C(O)-O-Ri and -C(O)-NH-Ri, where Ri is selected from aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, -Ci-Cg alkyl, -C 2 -Cg alkenyl, -C 2 -Cg alkynyl, substituted - Ci-Cg alkyl, substituted -C 2 -Cg alkenyl, substituted -C 2 -Cg alkynyl, -C 3 -C 12 cycloalkyl, -Cs-Ci 2 cycloalkenyl, substituted -C 3 -Ci 2 cycloalkyl, or substituted - C 3 -Ci 2 cycloalkenyl.
  • Ri is selected from aryl, substituted aryl, heteroaryl, substituted heteroaryl,
  • G can be -NH-SO 2 -NR 4 R 5 or -NHSO 2 -R 3 , where R 3 is selected from -Ci-C 8 alkyl, -C 2 -C 8 alkenyl, -C 2 -C 8 alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, -C 3 -Ci 2 cycloalkyl, -C 3 -Ci 2 cycloalkenyl, substituted -C 3 -Ci 2 cycloalkyl, or substituted - C 3 -Ci 2 cycloalkenyl, and R 4 and R 5 are each independently selected from hydrogen, -Ci-C 8 alkyl, -C 2 -C 8 alkenyl, -C 2 -C 8 alkynyl, substituted -Ci-C 8 alkyl, substituted -C 2 -C 8 alkenyl, substituted
  • X is substituted or unsubstituted aryl (e.g.,
  • A is -C(O)-O-Ri or -C(O)-NH-Ri, where Ri is -C 3 -Ci 2 cycloalkyl or substituted -C 3 -Ci 2 cycloalkyl.
  • G is -NHSO 2 -R 3 , where R 3 is selected from -C 3 -Ci 2 cycloalkyl or substituted -C 3 -Ci 2 cycloalkyl.
  • X and Y are independently selected from the group consisting of hydrogen, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, -Ci-Cs alkyl, -C 2 -Cs alkenyl, or -C 2 -Cs alkynyl, substituted -Ci-Cs alkyl, substituted -C 2 -Cs alkenyl, or substituted -C 2 -Cs alkyny, -C 3 -C 12 cycloalkyl, -C 3 -Ci 2 cycloalkenyl, substituted -C 3 -Ci 2 cycloalkyl, and substituted -C 3 -Ci 2 cycloalkeny
  • A is selected from the group consisting of -C(O)-Ri, - C(O)-O-Ri and -C(O)-NH-Ri, where Ri is selected from aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, -Ci-Cs alkyl, -C 2 -Cs alkenyl, -C 2 -Cs alkynyl, substituted -Ci-Cs alkyl, substituted -C 2 -Cs alkenyl, substituted -C 2 -Cs alkynyl, -C 3 -Ci 2 cycloalkyl, -C 3 -Ci 2 cycloalkenyl, substituted -C 3 -Ci 2 cycloalkyl, or substituted -C 3 -Ci 2 cycloalkenyl.
  • G can be - NH-SO 2 -NR 4 R 5 Or -NHSO 2 -R 3 , where R 3 is selected from -Ci-C 8 alkyl, -C 2 -C 8 alkenyl, -C 2 -C 8 alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, -C 3 -Ci 2 cycloalkyl, -C 3 -Ci 2 cycloalkenyl, substituted -C 3 -Ci 2 cycloalkyl, or substituted -C 3 -Ci 2 cycloalkenyl, and R 4 and R 5 are each independently selected from hydrogen, -Ci-C 8 alkyl, -C 2 -C 8 alkenyl, -C 2 - C 8 alkynyl, substituted -Ci-C 8 alkyl, substituted -C 2 -C 8 alkenyl, substituted
  • X and Y are independently selected from the group consisting of hydrogen, aryl, substituted aryl, heteroaryl, and substituted heteroaryl.
  • A is -C(O)-O-Ri or -C(O)-NH-Ri, where Ri is -Ci-C 8 alkyl, -C 2 -C 8 alkenyl, -C 2 -C 8 alkynyl, substituted -Ci-C 8 alkyl, substituted -C 2 -C 8 alkenyl, substituted -C 2 -C 8 alkynyl, -C 3 -C 12 cycloalkyl, -C 3 -C 12 cycloalkenyl, substituted - C3-C12 cycloalkyl, or substituted -C 3 -C 12 cycloalkenyl.
  • G is -NHSO2-R3, where R3 is selected from aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, -C 3 -C 12 cycloalkyl, -C 3 -C 12 cycloalkenyl, substituted -C 3 -C 12 cycloalkyl, or substituted -C 3 -C 12 cycloalkenyl.
  • X and Y are independently selected from the group consisting of aryl, substituted aryl, heteroaryl, and substituted heteroaryl.
  • A is -C(O)-O-Ri, where Ri is -C 3 -Ci 2 cycloalkyl or substituted -C 3 -Ci 2 cycloalkyl.
  • G is -NHSO 2 -R 3 , where R 3 is selected from -C 3 -Ci 2 cycloalkyl or substituted -C 3 - C 12 cycloalkyl.
  • X and Y are independently selected from the group consisting of aryl, substituted aryl, heteroaryl, and substituted heteroaryl.
  • A is - C(O)-NH-Ri, where Ri is -Ci-C 8 alkyl or substituted -Ci-C 8 alkyl.
  • G is -NHSO 2 - R 3 , where R 3 is selected from -C 3 -Ci 2 cycloalkyl or substituted -C 3 -Ci 2 cycloalkyl.
  • aryl substituted aryl; heteroaryl; substituted heteroaryl; and (vi) heterocycloalkyl or substituted heterocycloalkyl;
  • A, G, R 4 and R 5 are as defined in the first embodiment.
  • Xi-X 4 are independently selected from -CR 7 and N, where R 7 is as previously defined immediately above.
  • A is selected from the group consisting of -C(O)-Ri, -C(O)-O-Ri and -C(O)-NH-Ri, where Ri is selected from aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, -Ci-Cg alkyl, -C 2 -Cg alkenyl, -C 2 -Cg alkynyl, substituted - Ci-C 8 alkyl, substituted -C 2 -C 8 alkenyl, substituted -C 2 -C 8 alkynyl, -C 3 -Ci 2 cycloalkyl, -C 3 -Ci 2 cycloalkenyl, substituted -C 3 -Ci 2 cycloalkyl, or substituted - C 3 -Ci 2
  • G can be -NH-SO 2 -NR 4 R 5 Or -NHSO 2 -R 3 , where R 3 is selected from -Ci-C 8 alkyl, -C 2 -C 8 alkenyl, -C 2 -C 8 alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, -C 3 -Ci 2 cycloalkyl, -C 3 -Ci 2 cycloalkenyl, substituted -C 3 -Ci 2 cycloalkyl, or substituted - C 3 -Ci 2 cycloalkenyl, and R 4 and R 5 are each independently selected from hydrogen, -Ci-C 8 alkyl, -C 2 -C 8 alkenyl, -C 2 -C 8 alkynyl, substituted -Ci-C 8 alkyl, substituted -C 2 -C 8 alkenyl, substituted
  • X 1 -X 4 are independently selected from - CR 7 and N, where R 7 is as previously defined above.
  • A is -C(O)-O-Ri or -C(O)- NH-Ri, where Ri is -Ci-C 8 alkyl, -C 2 -C 8 alkenyl, -C 2 -C 8 alkynyl, substituted -C 1 - C 8 alkyl, substituted -C 2 -C 8 alkenyl, substituted -C 2 -C 8 alkynyl, -C 3 -C 12 cycloalkyl, -Cs-Ci 2 cycloalkenyl, substituted -C 3 -Ci 2 cycloalkyl, or substituted - C 3 -Ci 2 cycloalkenyl.
  • G is -NHSO 2 -R 3 , where R 3 is selected from aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, -C 3 - Ci 2 cycloalkyl, -C 3 -Ci 2 cycloalkenyl, substituted -C 3 -Ci 2 cycloalkyl, or substituted -C 3 -Ci 2 cycloalkenyl.
  • R 3 is selected from aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, -C 3 - Ci 2 cycloalkyl, -C 3 -Ci 2 cycloalkenyl, substituted -C 3 -Ci 2 cycloalkyl, or substituted -C 3 -Ci 2 cycloalkenyl.
  • Xi-X 4 are independently selected from -
  • A is -C(O)-O-Ri, where Ri is -C 3 -Ci 2 cycloalkyl or substituted -C 3 -Ci 2 cycloalkyl.
  • G is -NHSO 2 -R 3 , where R 3 is selected from -C 3 -Ci 2 cycloalkyl or substituted -C 3 -Ci 2 cycloalkyl.
  • Xi-X 4 are independently selected from -CR 7 and N, where R 7 is as previously defined above.
  • A is -C(O)-NH-Ri, where Ri is - Ci-C 8 alkyl or substituted -Ci-C 8 alkyl.
  • G is -NHSO 2 -R 3 , where R 3 is selected from -C 3 -Ci 2 cycloalkyl or substituted -C 3 -Ci 2 cycloalkyl.
  • A, G, R 4 and R 5 are are as defined in the first embodiment.
  • Xi-X 4 are independently selected from -CR 7 and N, where R 7 is as defined immediately above.
  • A is selected from the group consisting of -C(O)-R h -C(O)-O-Ri and -C(O)-NH-Ri, where Ri is selected from aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, -Ci-Cs alkyl, -C 2 -Cs alkenyl, -C 2 -Cs alkynyl, substituted -Ci-Cs alkyl, substituted -C 2 -C 8 alkenyl, substituted -C 2 -C 8 alkynyl, -C 3 -Ci 2 cycloalkyl, -C 3 -Ci 2 cycloalkenyl, substituted -C 3 -Ci 2 cycl
  • G can be -NH-SO 2 -NR 4 R 5 or -NHSO 2 -R 3 , where R 3 is selected from -Ci-C 8 alkyl, -C 2 -C 8 alkenyl, -C 2 -C 8 alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, -C 3 -Ci 2 cycloalkyl, -C 3 -Ci 2 cycloalkenyl, substituted -C 3 -Ci 2 cycloalkyl, or substituted -C 3 -Ci 2 cycloalkenyl, and R 4 and R 5 are each independently selected from hydrogen, -Ci-C 8 alkyl, -C 2 - C 8 alkenyl, -C 2 -C 8 alkynyl, substituted -Ci-C 8 alkyl, substituted -C 2 -C 8 alkenyl, substituted
  • Xi-X 4 are independently selected from - CR 7 and N, where R 7 is as previously defined above.
  • A is -C(O)-O-Ri or -C(O)- NH-Ri, where Ri is -Ci-C 8 alkyl, -C 2 -C 8 alkenyl, -C 2 -C 8 alkynyl, substituted -C 1 - C 8 alkyl, substituted -C 2 -C 8 alkenyl, substituted -C 2 -C 8 alkynyl, -C 3 -Ci 2 cycloalkyl, -C 3 -Ci 2 cycloalkenyl, substituted -C 3 -Ci 2 cycloalkyl, or substituted - C3-C12 cycloalkenyl.
  • G is -NHSO2-R3, where R 3 is selected from aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, -C 3 - C 12 cycloalkyl, -C 3 -C 12 cycloalkenyl, substituted -C 3 -C 12 cycloalkyl, or substituted -C 3 -C 12 cycloalkenyl.
  • R 3 is selected from aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, -C 3 - C 12 cycloalkyl, -C 3 -C 12 cycloalkenyl, substituted -C 3 -C 12 cycloalkyl, or substituted -C 3 -C 12 cycloalkenyl.
  • R 3 is selected from aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic,
  • A is -C(O)-O-Ri, where Ri is -C 3 -C 12 cycloalkyl or substituted -C 3 -C 12 cycloalkyl.
  • G is -NHSO2-R3, where R3 is selected from -C 3 -C 12 cycloalkyl or substituted -C 3 -C 12 cycloalkyl.
  • Xi -X 4 are independently selected from -CR 7 and N, where R 7 is as previously defined above.
  • A is -C(O)-NH-Ri, where Ri is - Ci-C 8 alkyl or substituted -Ci-C 8 alkyl.
  • G is -NHSO 2 -R 3 , where R 3 is selected from -C 3 -C 12 cycloalkyl or substituted -C 3 -Ci 2 cycloalkyl.
  • Yi-Y 3 are independently selected selected from CR 7 , N, NR 7 , S and O, wherein R 7 is independently selected at each occurrence from: (i) hydrogen; halogen; -NO 2 ; -CN;
  • M is O, S, NH; (iii) NR 4 R 5 ; (iv) -Ci-C 8 alkyl, -C 2 -C 8 alkenyl, or -C 2 -C 8 alkynyl each containing
  • A, G, R 4 and R 5 are are as defined in the first embodiment.
  • Yi-Y 3 are independently selected from -CR 7 , N, NR 7 , S and O, where R 7 is as previously defined immediately above.
  • A is selected from the group consisting of -C(O)-Ri, -C(O)-O-Ri and -C(O)-NH-Ri, where Ri is selected from aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, -Ci-Cg alkyl, -C 2 -Cg alkenyl, -C 2 -Cg alkynyl, substituted -Ci-Cg alkyl, substituted -C 2 -Cg alkenyl, substituted -C 2 -Cg alkynyl, - C 3 -Ci 2 cycloalkyl, -C 3 -Ci 2 cycloalkenyl, substituted -
  • G can be -NH-SO 2 -NR 4 R 5 or -NHSO 2 -R 3 , where R 3 is selected from -Ci-C 8 alkyl, -C 2 -C 8 alkenyl, -C 2 -C 8 alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, -C 3 -Ci 2 cycloalkyl, -C 3 -Ci 2 cycloalkenyl, substituted -C 3 -Ci 2 cycloalkyl, or substituted -C 3 -Ci 2 cycloalkenyl, and R 4 and R5 are each independently selected from hydrogen, -Ci-C 8 alkyl, -C 2 -C 8 alkenyl, -C 2 -C 8 alkynyl, substituted -Ci-C 8 alkyl, substituted -C 2 -C 8 alkenyl, substituted
  • Yi-Y 3 are independently selected from - CR 7 , N, NR 7 , S and O, where R 7 is as previously defined above.
  • A is -C(O)-O-Ri or -C(O)-NH-Ri, where Ri is -Ci-C 8 alkyl, -C 2 -C 8 alkenyl, -C 2 -C 8 alkynyl, substituted -Ci-C 8 alkyl, substituted -C 2 -C 8 alkenyl, substituted -C 2 -C 8 alkynyl, - C 3 -Ci 2 cycloalkyl, -C 3 -Ci 2 cycloalkenyl, substituted -C 3 -Ci 2 cycloalkyl, or substituted -C 3 -Ci 2 cycloalkenyl.
  • G is -NHSO 2 -R 3 , where R 3 is selected from aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, -C 3 -Ci 2 cycloalkyl, -C 3 -Ci 2 cycloalkenyl, substituted -C 3 -Ci 2 cycloalkyl, or substituted -C 3 -Ci 2 cycloalkenyl.
  • R 3 is selected from aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, -C 3 -Ci 2 cycloalkyl, -C 3 -Ci 2 cycloalkenyl, substituted -C 3 -Ci 2 cycloalkyl, or substituted -C 3 -Ci 2 cycloalkenyl.
  • Y 1 -Y 3 are independently selected from - CR 7 , N, NR 7
  • A is -C(O)-O-Ri, where Ri is -C 3 -C 12 cycloalkyl or substituted -C 3 -C 12 cycloalkyl.
  • G is -NHSO 2 - R3, where R3 is selected from -C 3 -C 12 cycloalkyl or substituted -C 3 -C 12 cycloalkyl.
  • Y 1 -Y 3 are independently selected from -CR 7 , N,
  • A is -C(O)-NH-Ri, where Ri is -Ci-C 8 alkyl or substituted -Ci-C 8 alkyl.
  • G is -NHSO 2 -R 3 , where R 3 is selected from -C 3 -Ci 2 cycloalkyl or substituted -C 3 -Ci 2 cycloalkyl.
  • -Ci-C 8 alkyl substituted -C 2 -C 8 alkenyl, or substituted -C 2 -C 8 alkynyl each containing O, 1, 2, or 3 heteroatoms selected from O, S or N; -C 3 -Ci 2 cycloalkyl, or substituted -C 3 -Ci 2 cycloalkyl; -C 3 -Ci 2 cycloalkenyl, or substituted -C 3 -Ci 2 cycloalkenyl;
  • A, G, R 4 and R 5 are are as defined in the first embodiment.
  • Y 1 -Y 3 are independently selected from -CR 7 , N, NR 7 , S and O, where R 7 is defined immediately above.
  • A is selected from the group consisting of -C(O)-Ri, -C(O)-O-Ri and -C(O)-NH-Ri, where Ri is selected from aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, -Ci-Cs alkyl, -C 2 -Cs alkenyl, -C 2 -Cs alkynyl, substituted - Ci-C 8 alkyl, substituted -C 2 -C 8 alkenyl, substituted -C 2 -C 8 alkynyl, -C 3 -Ci 2 cycloalkyl, -C 3 -Ci 2 cycloalkenyl, substituted -C 3 -Ci 2 cycloalkyl, or substituted - C 3 -Ci 2 cycloalkenyl.
  • G can be -NH-SO 2 -NR 4 R 5 or -NHSO 2 -R 3 , where R 3 is selected from -Ci-C 8 alkyl, -C 2 -C 8 alkenyl, -C 2 -C 8 alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, -C 3 -Ci 2 cycloalkyl, -C 3 -Ci 2 cycloalkenyl, substituted -C 3 -Ci 2 cycloalkyl, or substituted - C 3 -Ci 2 cycloalkenyl, and R 4 and R 5 are each independently selected from hydrogen, -Ci-C 8 alkyl, -C 2 -C 8 alkenyl, -C 2 -C 8 alkynyl, substituted -Ci-C 8 alkyl, substituted -C 2 -C 8 alkenyl, substituted
  • A is -C(O)-O-Ri or -C(O)-NH-Ri, where Ri is -Ci-C 8 alkyl, -C 2 -C 8 alkenyl, -C 2 -C 8 alkynyl, substituted -Ci-C 8 alkyl, substituted -C 2 -C 8 alkenyl, substituted -C 2 -C 8 alkynyl, - C 3 -Ci 2 cycloalkyl, -C 3 -Ci 2 cycloalkenyl, substituted -C 3 -Ci 2 cycloalkyl, or substituted -C 3 -Ci 2 cycloalkenyl.
  • G is -NHSO 2 -R 3 , where R 3 is selected from aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, -C 3 -Ci 2 cycloalkyl, -C 3 -Ci 2 cycloalkenyl, substituted -C 3 -Ci 2 cycloalkyl, or substituted -C 3 -Ci 2 cycloalkenyl.
  • Yi-Y 3 are independently selected from - CR 7 , N, NR 7 , S and O, where R 7 is as previously defined above.
  • A is -C(O)-O-Ri, where Ri is -C 3 -Ci 2 cycloalkyl or substituted -C 3 -Ci 2 cycloalkyl.
  • G is -NHSO 2 - R 3 , where R 3 is selected from -C 3 -Ci 2 cycloalkyl or substituted -C 3 -Ci 2 cycloalkyl.
  • Y 1 -Y 3 are independently selected from -CR 7 , N, NR 7 , S and O, where R 7 is as previously defined above.
  • A is -C(O)-NH-Ri, where Ri is -Ci-C 8 alkyl or substituted -Ci-C 8 alkyl.
  • G is -NHSO 2 -R 3 , where R 3 is selected from -C 3 -C 12 cycloalkyl or substituted -C 3 -C 12 cycloalkyl.
  • Representative compounds of the invention include, but are not limited to, the following compounds (Table 1) according to Formula IX:
  • the present invention also features pharmaceutical compositions comprising a compound of the present invention, or a pharmaceutically acceptable salt, ester or prodrug thereof.
  • the pharmaceutical compositions of the present invention may further contain other anti-HCV agents.
  • anti-HCV agents include, but are not limited to, interferon (e.g., alpha-interferon, beta-interferon, consensus interferon, pegylated interferon, or albumin or other conjugated interferon), ribavirin, and amantadine.
  • interferon e.g., alpha-interferon, beta-interferon, consensus interferon, pegylated interferon, or albumin or other conjugated interferon
  • ribavirin e.g., ribavirin
  • amantadine e.g., S. Tan, A. Pause, Y. Shi, N. Sonenberg, Hepatitis C Therapeutics: Current Status and
  • compositions of the present invention may further contain other HCV protease inhibitors.
  • compositions of the present invention may further comprise inhibitor(s) of other targets in the HCV life cycle, including, but not limited to, helicase, polymerase, metalloprotease, and internal ribosome entry site (IRES).
  • inhibitor(s) of other targets in the HCV life cycle including, but not limited to, helicase, polymerase, metalloprotease, and internal ribosome entry site (IRES).
  • compositions of the present invention may further comprise another anti-viral, anti-bacterial, anti- fungal or anti-cancer agent, or an immune modulator, or another thearapeutic agent.
  • the present invention includes methods of treating hepatitis C infections in a subject in need of such treatment by administering to said subject an anti-HCV virally effective amount of a compound of the present invention or a pharmaceutically acceptable salt, ester, or prodrug thereof.
  • the present invention includes methods of treating hepatitis C infections in a subject in need of such treatment by administering to said subject an anti-HCV virally effective amount or an inhibitory amount of a pharmaceutical composition of the present invention.
  • An additional embodiment of the present invention includes methods of treating biological samples by contacting the biological samples with the compounds of the present invention.
  • Yet a further aspect of the present invention is a process of making any of the compounds delineated herein employing any of the synthetic means delineated herein.
  • Ci-C 6 alkyl refers to saturated, straight- or branched-chain hydrocarbon radicals containing between one and six, or one and eight carbon atoms, respectively.
  • Examples of Ci-C 6 alkyl radicals include, but are not limited to, methyl, ethyl, propyl, isopropyl, n-butyl, tert-butyl, neopentyl, n-hexyl radicals; and examples of Ci-Cs alkyl radicals include, but are not limited to, methyl, ethyl, propyl, isopropyl, n-butyl, tert-butyl, neopentyl, n- hexyl, heptyl, octyl radicals.
  • C 2 -C 6 alkenyl or "C 2 -C 8 alkenyl,” as used herein, denote a monovalent group derived from a hydrocarbon moiety by the removal of a single hydrogen atom wherein the hydrocarbon moiety has at least one carbon-carbon double bond and contains from two to six, or two to eight carbon atoms, respectively.
  • Alkenyl groups include, but are not limited to, for example, ethenyl, propenyl, butenyl, l-methyl-2-buten-l-yl, heptenyl, octenyl and the like.
  • C 2 -C 6 alkynyl or "C 2 -Cg alkynyl,” as used herein, denote a monovalent group derived from a hydrocarbon moiety by the removal of a single hydrogen atom wherein the hydrocarbon moiety has at least one carbon-carbon triple bond and contains from two to six, or two to eight carbon atoms, respectively.
  • Representative alkynyl groups include, but are not limited to, for example, ethynyl, 1-propynyl, 1-butynyl, heptynyl, octynyl and the like.
  • C 3 -C 8 -cycloalkyl denotes a monovalent group derived from a monocyclic or polycyclic saturated carbocyclic ring compound by the removal of a single hydrogen atom where the saturated carbocyclic ring compound has from 3 ot 8, or from 3 to 12, ring atoms, respectively.
  • C 3 -C 8 -cycloalkyl examples include, but not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopentyl and cyclooctyl; and examples of C 3 -Ci 2 -cycloalkyl include, but not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, bicyclo [2.2.1] heptyl, and bicyclo [2.2.2] octyl.
  • Q-Cg-cycloalkenyl or "C 3 -Ci 2 -cycloalkenyl” as used herein, denote a monovalent group derived from a monocyclic or polycyclic carbocyclic ring compound having at least one carbon-carbon double bond by the removal of a single hydrogen atom where the carbocyclic ring compound has from 3 ot 8, or from 3 to 12, ring atoms, respectively.
  • C 3 -C 8 -cycloalkenyl examples include, but not limited to, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, and the like; and examples of C 3 -Ci 2 -cycloalkenyl include, but not limited to, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, and the like.
  • aryl refers to a mono- or bicyclic carbocyclic ring system having one or two aromatic rings including, but not limited to, phenyl, naphthyl, tetrahydronaphthyl, indanyl, idenyl and the like.
  • arylalkyl refers to a Ci-C 3 alkyl or Ci-C 6 alkyl residue attached to an aryl ring. Examples include, but are not limited to, benzyl, phenethyl and the like.
  • heteroaryl refers to a mono-, bi-, or tri-cyclic aromatic radical or ring having from five to ten ring atoms of which at least one ring atom is selected from S, O and N; wherein any N or S contained within the ring may be optionally oxidized.
  • Heteroaryl includes, but is not limited to, pyridinyl, pyrazinyl, pyrimidinyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, isooxazolyl, thiadiazolyl, oxadiazolyl, thiophenyl, furanyl, quinolinyl, isoquinolinyl, benzimidazolyl, benzooxazolyl, quinoxalinyl, and the like.
  • heteroarylalkyl refers to a C 1 -C 3 alkyl or Ci-C 6 alkyl residue residue attached to a heteroaryl ring. Examples include, but are not limited to, pyridinylmethyl, pyrimidinylethyl and the like.
  • heterocyclic and “heterocycloalkyl,” can be used interchangeably, and refer to a non-aromatic 3-, 4-, 5-, 6- or 7-membered ring or a bi- or tri-cyclic group fused system, where (i) each ring contains between one and three heteroatoms independently selected from oxygen, sulfur and nitrogen, (ii) each 5-membered ring has 0 to 1 double bonds and each 6-membered ring has 0 to 2 double bonds, (iii) the nitrogen and sulfur heteroatoms may optionally be oxidized, (iv) the nitrogen heteroatom may optionally be quaternized, and (iv) any of the above rings may be fused to a benzene ring.
  • heterocycloalkyl groups include, but are not limited to, [l,3]dioxolane, pyrrolidinyl, pyrazolinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, piperidinyl, piperazinyl, oxazolidinyl, isoxazolidinyl, morpholinyl, thiazolidinyl, isothiazolidinyl, and tetrahydrofuryl.
  • Such heterocycloalkyl groups may be further substituted to give substituted heterocycloalkyl.
  • substituted refers to independent replacement of one, two, or three or more of the hydrogen atoms thereon with substituents including, but not limited to, -F, -Cl, -Br, -I, -OH, protected hydroxy, -NO 2 , -CN, - NH 2 , protected amino, -NH -d-C ⁇ -alkyl, -NH -C 2 -C 12 -alkenyl, -NH -C 2 -C 12 - alkenyl, -NH -C 3 -C 12 -cycloalkyl, -NH -aryl, -NH -heteroaryl, -NH - heterocycloalkyl, -dialkylamino, -diarylamino, -diheteroarylamino, -0-C 1 -C 12 - alkyl, -O-C 2 -C 12 -alkenyl,
  • each substituent in a substituted moiety is additionally optionally substituted with one or more groups, each group being independently selected from -F, -Cl, -Br, -I, -OH, -NO 2 , -CN, or -NH 2 .
  • any of the aryls, substituted aryls, heteroaryls and substituted heteroaryls described herein can be any aromatic group.
  • Aromatic groups can be substituted or unsubstituted. It is understood that any alkyl, alkenyl, alkynyl, cycloalkyl and cycloalkenyl moiety described herein can also be an aliphatic group, an alicyclic group or a heterocyclic group.
  • an "aliphatic group” is non-aromatic moiety that may contain any combination of carbon atoms, hydrogen atoms, halogen atoms, oxygen, nitrogen or other atoms, and optionally contain one or more units of unsaturation, e.g., double and/or triple bonds.
  • An aliphatic group may be straight chained, branched or cyclic and preferably contains between about 1 and about 24 carbon atoms, more typically between about 1 and about 12 carbon atoms.
  • aliphatic groups include, for example, polyalkoxyalkyls, such as polyalkylene glycols, polyamines, and polyimines, for example. Such aliphatic groups may be further substituted. It is understood that aliphatic groups may be used in place of the alkyl, alkenyl, alkynyl, alkylene, alkenylene, and alkynylene groups described herein.
  • alicyclic denotes a monovalent group derived from a monocyclic or polycyclic saturated carbocyclic ring compound by the removal of a single hydrogen atom. Examples include, but not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, bicyclo [2.2.1] heptyl, and bicyclo [2.2.2] octyl. Such alicyclic groups may be further substituted.
  • alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, arylalkyl, heteroarylalkyl, and heterocycloalkyl are intended to be monovalent or divalent.
  • alkylene, alkenylene, and alkynylene, cycloaklylene, cycloalkenylene, cycloalkynylene, arylalkylene, hetoerarylalkylene and heterocycloalkylene groups are to be included in the above definitions, and are applicable to provide the formulas herein with proper valency.
  • hydroxy activating group refers to a labile chemical moiety which is known in the art to activate a hydroxy group so that it will depart during synthetic procedures such as in a substitution or elimination reactions.
  • hydroxy activating group include, but not limited to, mesylate, tosylate, triflate, /?-nitrobenzoate, phosphonate and the like.
  • activated hydroxy refers to a hydroxy group activated with a hydroxy activating group, as defined above, including mesylate, tosylate, triflate, p-nitrobenzoate, phosphonate groups, for example.
  • protected hydroxy refers to a hydroxy group protected with a hydroxy protecting group, as defined above, including benzoyl, acetyl, trimethylsilyl, triethylsilyl, methoxymethyl groups, for example.
  • halo and halogen, as used herein, refer to an atom selected from fluorine, chlorine, bromine and iodine.
  • the compounds described herein contain one or more asymmetric centers and thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (R)- or (S)- , or as (D)- or (L)- for amino acids.
  • the present invention is meant to include all such possible isomers, as well as their racemic and optically pure forms.
  • Optical isomers may be prepared from their respective optically active precursors by the procedures described above, or by resolving the racemic mixtures. The resolution can be carried out in the presence of a resolving agent, by chromatography or by repeated crystallization or by some combination of these techniques which are known to those skilled in the art.
  • subject refers to a mammal.
  • a subject therefore refers to, for example, dogs, cats, horses, cows, pigs, guinea pigs, and the like.
  • the subject is a human.
  • the subject may be referred to herein as a patient.
  • the term "pharmaceutically acceptable salt” refers to those salts of the compounds formed by the process of the present invention which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio.
  • Pharmaceutically acceptable salts are well known in the art.
  • salts in detail in J. Pharmaceutical Sciences, 66: 1-19 (1977).
  • the salts can be prepared in situ during the final isolation and purification of the compounds of the invention, or separately by reacting the free base function with a suitable organic acid.
  • suitable organic acid examples include, but are not limited to, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange.
  • salts include, but are not limited to, adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2- hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pam
  • alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like.
  • Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, alkyl having from 1 to 6 carbon atoms, sulfonate and aryl sulfonate.
  • hydroxy protecting group refers to a labile chemical moiety which is known in the art to protect a hydroxy group against undesired reactions during synthetic procedures. After said synthetic procedure(s) the hydroxy protecting group as described herein may be selectively removed.
  • Hydroxy protecting groups as known in the are described generally in T. H. Greene and P. G., S.Wuts, Protective Groups in Organic Synthesis, 3rd edition, John Wiley & Sons, New York (1999).
  • Examples of hydroxy protecting groups include benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4- methoxybenzyloxycarbonyl, methoxycarbonyl, tert-butoxycarbonyl, isopropoxycarbonyl, diphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2- (trimethylsilyl)ethoxycarbonyl, 2-furfuryloxycarbonyl, allyloxycarbonyl, acetyl, formyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, methyl, t-butyl, 2,2,2-t
  • Preferred hydroxy protecting groups for the present invention are acetyl (Ac or -C(O)CHs), benzoyl (Bz or -C(O)C 6 Hs), and trimethylsilyl (TMS or-Si(CH 3 ) 3 ).
  • amino protecting group refers to a labile chemical moiety which is known in the art to protect an amino group against undesired reactions during synthetic procedures. After said synthetic procedure(s) the amino protecting group as described herein may be selectively removed. Amino protecting groups as known in the are described generally in T. H. Greene and P. G. M. Wuts, Protective Groups in Organic Synthesis, 3rd edition, John
  • amino protecting groups include, but are not limited to, t-butoxycarbonyl, 9-fluorenylmethoxycarbonyl, benzyloxycarbonyl, and the like.
  • pharmaceutically acceptable ester refers to esters of the compounds formed by the process of the present invention which hydro lyze in vivo and include those that break down readily in the human body to leave the parent compound or a salt thereof.
  • Suitable ester groups include, for example, those derived from pharmaceutically acceptable aliphatic carboxylic acids, particularly alkanoic, alkenoic, cycloalkanoic and alkanedioic acids, in which each alkyl or alkenyl moiety advantageously has not more than 6 carbon atoms.
  • Examples of particular esters include, but are not limited to, formates, acetates, propionates, butyrates, acrylates and ethylsuccinates.
  • prodrugs refers to those prodrugs of the compounds formed by the process of the present invention which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals with undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use, as well as the zwitterionic forms, where possible, of the compounds of the present invention.
  • Prodrug as used herein means a compound which is convertible in vivo by metabolic means (e.g. by hydrolysis) to afford any compound delineated by the formulae of the instant invention.
  • prodrugs are known in the art, for example, as discussed in Bundgaard, (ed.), Design of Prodrugs, Elsevier (1985); Widder, et al. (ed.), Methods in Enzymology, vol. 4, Academic Press (1985); Krogsgaard-Larsen, et al., (ed). "Design and Application of Prodrugs, Textbook of Drug Design and Development, Chapter 5, 113-191 (1991); Bundgaard, et al., Journal of Drug Deliver Reviews, 8:1-38(1992); Bundgaard, J. of Pharmaceutical Sciences, 77:285 et seq.
  • acyl includes residues derived from acids, including but not limited to carboxylic acids, carbamic acids, carbonic acids, sulfonic acids, and phosphorous acids. Examples include aliphatic carbonyls, aromatic carbonyls, aliphatic sulfonyls, aromatic sulfmyls, aliphatic sulfinyls, aromatic phosphates and aliphatic phosphates. Examples of aliphatic carbonyls include, but are not limited to, acetyl, propionyl, 2-fluoroacetyl, butyryl, 2-hydroxy acetyl, and the like.
  • aprotic solvent refers to a solvent that is relatively inert to proton activity, i.e., not acting as a proton-donor.
  • examples include, but are not limited to, hydrocarbons, such as hexane and toluene, for example, halogenated hydrocarbons, such as, for example, methylene chloride, ethylene chloride, chloroform, and the like, heterocyclic compounds, such as, for example, tetrahydrofuran and N-methylpyrrolidinone, and ethers such as diethyl ether, bis-methoxymethyl ether.
  • solvents are well known to those skilled in the art, and individual solvents or mixtures thereof may be preferred for specific compounds and reaction conditions, depending upon such factors as the solubility of reagents, reactivity of reagents and preferred temperature ranges, for example. Further discussions of aprotic solvents may be found in organic chemistry textbooks or in specialized monographs, for example: Organic Solvents Physical Properties and Methods of Purification, 4th ed., edited by John A. Riddick et al. , Vol. II, in the Techniques of Chemistry Series, John Wiley & Sons, NY, 1986.
  • protogenic organic solvent refers to a solvent that tends to provide protons, such as an alcohol, for example, methanol, ethanol, propanol, isopropanol, butanol, t-butanol, and the like.
  • solvents are well known to those skilled in the art, and individual solvents or mixtures thereof may be preferred for specific compounds and reaction conditions, depending upon such factors as the solubility of reagents, reactivity of reagents and preferred temperature ranges, for example. Further discussions of protogenic solvents may be found in organic chemistry textbooks or in specialized monographs, for example: Organic Solvents Physical Properties and Methods of Purification, 4th ed., edited by John A. Riddick et al., Vol. II, in the Techniques of Chemistry Series. John Wiley & Sons, NY, 1986.
  • stable refers to compounds which possess stability sufficient to allow manufacture and which maintains the integrity of the compound for a sufficient period of time to be useful for the purposes detailed herein (e.g., therapeutic or prophylactic administration to a subject).
  • the synthesized compounds can be separated from a reaction mixture and further purified by a method such as column chromatography, high pressure liquid chromatography, or recrystallization. As can be appreciated by the skilled artisan, further methods of synthesizing the compounds of the formulae herein will be evident to those of ordinary skill in the art. Additionally, the various synthetic steps may be performed in an alternate sequence or order to give the desired compounds.
  • the compounds of this invention may be modified by appending various functionalities via any synthetic means delineated herein to enhance selective biological properties.
  • modifications are known in the art and include those which increase biological penetration into a given biological system (e.g., blood, lymphatic system, central nervous system), increase oral availability, increase solubility to allow administration by injection, alter metabolism and alter rate of excretion.
  • compositions of the present invention comprise a therapeutically effective amount of a compound of the present invention formulated together with one or more pharmaceutically acceptable carriers.
  • pharmaceutically acceptable carrier means a non-toxic, inert solid, semi-solid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type.
  • materials which can serve as pharmaceutically acceptable carriers are sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil; safflower oil; sesame oil; olive oil; corn oil and soybean oil; glycols; such a propylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffering agents such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol, and phosphate buffer solutions, as well as other non-toxic compatible lubricants such as sodium lauryl sulf
  • compositions of this invention can be administered to humans and other animals orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, or drops), buccally, or as an oral or nasal spray.
  • compositions of this invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir, preferably by oral administration or administration by injection.
  • the pharmaceutical compositions of this invention may contain any conventional non-toxic pharmaceutically-acceptable carriers, adjuvants or vehicles.
  • the pH of the formulation may be adjusted with pharmaceutically acceptable acids, bases or buffers to enhance the stability of the formulated compound or its delivery form.
  • parenteral as used herein includes subcutaneous, intracutaneous, intravenous, intramuscular, intraarticular, intraarterial, intrasynovial, intrasternal, intrathecal, intralesional and intracranial injection or infusion techniques.
  • Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.
  • the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsif ⁇ ers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3- butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
  • the oral compositions can also include adjuvants such as wetting agents,
  • sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents.
  • the sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol.
  • acceptable vehicles and solvents that may be employed are water, Ringer's solution, U.S. P. and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil can be employed including synthetic mono- or diglycerides.
  • fatty acids such as oleic acid are used in the preparation of injectables.
  • the injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.
  • the rate of drug release can be controlled.
  • biodegradable polymers include poly(orthoesters) and poly(anhydrides).
  • Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissues.
  • compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
  • suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
  • Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules.
  • the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or: a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite
  • the dosage form may also comprise buffering agents.
  • Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
  • the active compounds can also be in micro-encapsulated form with one or more excipients as noted above.
  • the solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings, release controlling coatings and other coatings well known in the pharmaceutical formulating art.
  • the active compound may be admixed with at least one inert diluent such as sucrose, lactose or starch.
  • Such dosage forms may also comprise, as is normal practice, additional substances other than inert diluents, e.g., tableting lubricants and other tableting aids such a magnesium stearate and microcrystalline cellulose.
  • the dosage forms may also comprise buffering agents. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner.
  • buffering agents include polymeric substances and waxes.
  • Dosage forms for topical or transdermal administration of a compound of this invention include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches.
  • the active component is admixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers as may be required.
  • Ophthalmic formulation, ear drops, eye ointments, powders and solutions are also contemplated as being within the scope of this invention.
  • the ointments, pastes, creams and gels may contain, in addition to an active compound of this invention, excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
  • Powders and sprays can contain, in addition to the compounds of this invention, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances.
  • Sprays can additionally contain customary propellants such as chlorofluorohydrocarbons.
  • Transdermal patches have the added advantage of providing controlled delivery of a compound to the body.
  • dosage forms can be made by dissolving or dispensing the compound in the proper medium.
  • Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate can be controlled by either providing a rate controlling membrane or by dispersing the compound in a polymer matrix or gel.
  • An inhibitory amount or dose of the compounds of the present invention may range from about 0.1 mg/Kg to about 500 mg/Kg, alternatively from about 1 to about 50 mg/Kg. Inhibitory amounts or doses will also vary depending on route of administration, as well as the possibility of co-usage with other agents.
  • viral infections are treated or prevented in a subject such as a human or lower mammal by administering to the subject an anti-hepatitis C virally effective amount or an inhibitory amount of a compound of the present invention, in such amounts and for such time as is necessary to achieve the desired result.
  • An additional method of the present invention is the treatment of biological samples with an inhibitory amount of a compound of composition of the present invention in such amounts and for such time as is necessary to achieve the desired result.
  • anti-hepatitis C virally effective amount of a compound of the invention, as used herein, mean a sufficient amount of the compound so as to decrease the viral load in a biological sample or in a subject.
  • an anti-hepatitis C virally effective amount of a compound of this invention will be at a reasonable benefit/risk ratio applicable to any medical treatment.
  • inhibitory amount of a compound of the present invention means a sufficient amount to decrease the hepatitis C viral load in a biological sample or a subject. It is understood that when said inhibitory amount of a compound of the present invention is administered to a subject it will be at a reasonable benefit/risk ratio applicable to any medical treatment as determined by a physician.
  • biological sample(s), means a substance of biological origin intended for administration to a subject. Examples of biological samples include, but are not limited to, blood and components thereof such as plasma, platelets, subpopulations of blood cells and the like; organs such as kidney, liver, heart, lung, and the like; sperm and ova; bone marrow and components thereof; or stem cells.
  • another embodiment of the present invention is a method of treating a biological sample by contacting said biological sample with an inhibitory amount of a compound or pharmaceutical composition of the present invention.
  • a maintenance dose of a compound, composition or combination of this invention may be administered, if necessary.
  • the dosage or frequency of administration, or both may be reduced, as a function of the symptoms, to a level at which the improved condition is retained when the symptoms have been alleviated to the desired level, treatment should cease.
  • an additional method of the present invention is the treatment of biological samples with an inhibitory amount of a compound of the present invention in such amounts and for such time as is necessary to inhibit viral replication and/or reduce viral load.
  • inhibitory amount means a sufficient amount to inhibit viral replication and/or decrease the hepatitis C viral load in a biological sample.
  • biological sample(s) as used herein means a substance of biological origin intended for administration to a subject.
  • biological samples include, but are not limited to blood and components thereof such as plasma, platelets, subpopulations of blood cells and the like; organs such as kidney, liver, heart, lung, and the like; sperm and ova; bone marrow and components thereof; or stem cells.
  • another embodiment of the present invention is a method of treating a biological sample by contacting said biological sample with an inhibitory amount of a compound or pharmaceutical composition of the present invention. It will be understood, however, that the total daily usage of the compounds and compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment.
  • the specific inhibitory dose for any particular patient will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed; and like factors well known in the medical arts.
  • the total daily inhibitory dose of the compounds of this invention administered to a subject in single or in divided doses can be in amounts, for example, from 0.01 to 50 mg/kg body weight or more usually from 0.1 to 25 mg/kg body weight.
  • Single dose compositions may contain such amounts or submultiples thereof to make up the daily dose.
  • treatment regimens according to the present invention comprise administration to a patient in need of such treatment from about 10 mg to about 1000 mg of the compound(s) of this invention per day in single or multiple doses.
  • ACN for acetonitrile
  • Ac for acetyl
  • CDI for carbonyldiimidazole
  • dba for dibenzylidene acetone
  • DIAD for diisopropylazodicarboxylate
  • DMAP for dimethylaminopyridine
  • DMSO dimethyl sulfoxide
  • dppb diphenylphosphino butane
  • EtOAc ethyl acetate
  • HATU 2-(7-Aza- 1 H-benzotriazole- 1 -yl)- 1 , 1 ,3 ,3-tetramethyluronium hexafluorophosphate
  • iPrOH for isopropanol
  • NaHMDS sodium bis(trimethylsilyl)amide
  • POPd for dihydrogen dichlorobis(di-tert-butylphosphino)palladium(II); TBAHS for tetrabutyl ammonium hydrogen sulfate;
  • Tris for Tris(hydroxymethyl)aminomethane
  • BME for 2-mercaptoethanol
  • DAST for diethylaminosulfur trifluoride
  • DABCYL 6-(N-4'-carboxy-4-(dimethylamino)azobenzene)- aminohexyl- l-O-(2-cyanoethyl)-(N,N-diisopropyl)-phosphoramidite
  • DIAD for diisopropyl azodicarboxylate
  • DIBAL-H for diisobutylaluminum hydride
  • DMEM Dulbecco's Modified Eagles Media
  • DMF N,N-dimethyl formamide
  • DMSO dimethylsulfoxide
  • DUPHOS dimethylsulfoxide
  • KHMDS potassium bis(trimethylsilyl) amide
  • TPP or PPI1 3 for triphenylphosphine
  • tBOC or Boc for tert-butyloxy carbonyl
  • Scheme 1 describes the synthesis of intermediate Ig.
  • the cyclic peptide precursor Ig was synthesized from Boc-L-2-amino-8-nonenoic acid Ia and cis-L- hydroxyproline methyl ester Ib via steps A-D set forth generally in Scheme 1.
  • steps A-D set forth generally in Scheme 1.
  • Other amino acid derivatives containing a terminal alkene may be used in place of Ia in order to create varied macrocyclic structures (for further details see WO/0059929).
  • Scheme 2 illustrates the general synthetic method of triazole analogs.
  • Triazoles (2-2) were synthesized from alkynes (2-1) with TMSN3, but not limited to TMSN3.
  • the alkynes (2-1) are commercially available or made by the Sonogashira reaction with primary alkyne (2-8) and aryl halide (2-9).
  • Sonogashira reaction see: Sonogashira, Comprehensive Organic Synthesis, Volume 3, Chapters 2,4 and Sonogashira, Synthesis 1977, 777.
  • Intermediate (3-1) was synthesized under the conditions with macrocyclic mesylate (2-3) and triazoles (2-2) as described in Scheme 2. Intermediate (3-1) may then undergo Suzuki coupling reactions, Sonogashira reactions, or Stille couplings at the position occupied by the halide or OTf.
  • Suzuki coupling reaction see: A. Suzuki, Pure Appl. Chem. 1991, 63, 419-422 and A. R. Martin, Y. Yang, Acta Chem. Scand. 1993, 47, 221-230.
  • Sonogashira reaction see: Sonogashira, Comprehensive Organic Synthesis, Volume 3, Chapters 2,4 and Sonogashira, Synthesis 1977, 777.
  • Stille coupling reaction see: J.
  • Scheme 4 illustrates the modification of the N-terminal and C-teminal of the macrocycle.
  • Deprotection of the Boc moiety with an acid yields compounds of formula (4-2).
  • the amino moiety of formula (4-2) can be alkylated or acylated with appropriate alkyl halide or acyl groups to give compounds of formula (4-3).
  • Compounds of formula (4-3) can be hydrolyzed with base such as lithium hydroxide to free up the acid moiety of formula (4-4).
  • Subsequent activation of the acid moiety followed by treatment with appropriate acyl or sulfonyl groups to provide compounds of formula (4-5).
  • the sulfonamides (5-2) were prepared from the corresponding acids (5-1) by subjecting the acid to a coupling reagent (i.e. CDI, HATU, DCC, EDC and the like) at RT or at elevated temperature, with the subsequent addition of the corresponding sulfonamide Rs-S(O) 2 -NH 2 in the presence of base wherein R3 is as previously defined.
  • a coupling reagent i.e. CDI, HATU, DCC, EDC and the like
  • the dipeptide Ic (1.9Ig) was dissolved in 15 mL of dioxane and 15 mL of 1 N LiOH aqueous solution and the hydrolysis reaction was carried out at RT for 4 hours.
  • the reaction mixture was acidified by 5% citric acid and extracted with 100 mL EtOAc, and followed by washing with water 2x20 ml, and brine 2x20 ml, respectively.
  • the organic phase was dried over anhydrous Na 2 SO 4 and then removed in vacuum, yielding the free carboxylic acid compound Id (1.79g, 97%), which was used for next step synthesis without need for further purification.
  • MS found 516.28, M+Na + .
  • Step 3a Alkyne Formation
  • MS (ESI): m/z 216.17 [M+H]
  • the 4-(2-thiazolyl)-5-(p-methoxyphenyl) triazole was prepared by adding to a pressure tube the compound (0.3g) from step 3a, 0.74ml of trimethylsilyl azide, and 4ml of xylenes and heating the mixture to 14O 0 C for 48 hours.
  • the reaction mixture was directly separated by silica column to afford a brown liquid after purification (0.18g, 50%).
  • the title compound was prepared by dissolving the title compound from step 3 c in 2 mL of dioxane and 1 mL of 1 N LiOH aqueous solution. The resulting reaction mixture was stirred at RT for 8 hours. The pH of the reaction mixture was adjusted to 3 with citric acid; then the reaction mixture was extracted with EtOAc, and washed with brine and water. The organic solution was concentrated in vacuo for purification by HPLC afforded a yellow powder after lyophilization (lOmg, yield 34%).
  • Example 4 to Example 21 were made with different triazoles following the similar procedures described in Example 3.
  • Example 23 to Example 41 were made with different sulfonamides following the similar procedures described in Example 22.
  • Example 44 to Example 92 are made following the procedures described in Examples 22 or 42.
  • the title compound was prepared using commercially available Boc-cis-L- hydroxyproline and D- ⁇ -vinyl cyclopropane amine acid ethyl ester Ie via condition similar to those described in step Ic of Example 1.
  • the title compound was prepared from Boc-protected dipeptide 93a via conditions similar to those described in step 43a of Example 43.
  • the title compound was prepared from acid 93g via conditions similar to those described in Example 22.
  • the title compound was prepared from bromotriazole 93g and 2-fluoropyridin-3- ylboronic acid via conditions similar to those described in step 93h of Example 93.
  • Step 96a The title compound was prepared from bromotriazole 93g and phenylboronic acid via conditions similar to those described in step 93h of Example 93.
  • the title compound was prepared from acid 96a via conditions similar to those described in Example 22.
  • the title compound was prepared from bromotriazole 93g and naphthalen-2- ylboronic acid via conditions similar to those described in step 93h of Example 93.
  • Step 100a The title compound was prepared from bromotriazole 93g and 2- methoxypyrimidin-5-ylboronic acid via conditions similar to those described in step 93h of Example 93.
  • Step 100b The title compound was prepared from acid 100a via conditions similar to those described in Example 22.
  • the title compound was prepared from bromotriazole 101 and A- (cyanomethyl)phenylboronic acid via conditions similar to those described in Example 102.
  • the compounds of the present invention exhibit potent inhibitory properties against the HCV NS3 protease.
  • the following examples describe assays in which the compounds of the present invention can be tested for anti-HCV effects.
  • HCV protease activity and inhibition is assayed using an internally quenched fluorogenic substrate.
  • a DABCYL and an EDANS group are attached to opposite ends of a short peptide. Quenching of the EDANS fluorescence by the DABCYL group is relieved upon proteolytic cleavage. Fluorescence is measured with a Molecular Devices Fluoromax (or equivalent) using an excitation wavelength of 355 nm and an emission wavelength of 485 nm.
  • the assay is run in Corning white half-area 96-well plates (VWR 29444- 312 [Corning 3693]) with full-length NS3 HCV protease Ib tethered with NS4A co factor (final enzyme concentration 1 to 15 nM).
  • the assay buffer is complemented with 10 ⁇ M NS4A cofactor Pep 4A (Anaspec 25336 or in-house, MW 1424.8).
  • RET Sl (Ac-Asp-Glu-Asp(EDANS)-Glu-Glu-Abu-[COO]Ala-Ser- Lys-(D ABCYL)-NH 2i. AnaSpec 22991, MW 1548.6) is used as the fiuorogenic peptide substrate.
  • the assay buffer contains 50 mM Hepes at pH 7.5, 30 mM NaCl and 10 mM BME. The enzyme reaction is followed over a 30 minutes time course at room temperature in the absence and presence of inhibitors.
  • HCV Inh 1 (Anaspec 25345, MW 796.8) Ac-Asp- Glu-Met-Glu-Glu-Cys-OH, [-20 0 C] and HCV Inh 2 (Anaspec 25346, MW 913.1) Ac-Asp-Glu-Dif-Cha-Cys-OH, are used as reference compounds.
  • HCV Cell Based Assay Quantification of HCV replicon RNA (HCV Cell Based Assay) is accomplished using the Huh 11-7 cell line (Lohmann, et al Science 285: 110-113, 1999). Cells are seeded at 4x10 3 cells/well in 96 well plates and fed media containing DMEM (high glucose), 10% fetal calf serum, penicillin-streptomycin and non-essential amino acids. Cells are incubated in a 7.5% CO 2 incubator at 37 0 C. At the end of the incubation period, total RNA is extracted and purified from cells using Ambion RNAqueous 96 Kit (Catalog No. AMI 812).
  • primers specific for HCV mediate both the reverse transcription of the HCV RNA and the amplification of the cDNA by polymerase chain reaction (PCR) using the TaqMan One-Step RT-PCR Master Mix Kit (Applied Biosystems catalog no. 4309169).
  • PCR polymerase chain reaction
  • Detection of the RT-PCR product is accomplished using the Applied Biosystems (ABI) Prism 7500 Sequence Detection System (SDS) that detects the fluorescence that is emitted when the probe, which is labeled with a fluorescence reporter dye and a quencher dye, is degraded during the PCR reaction.
  • SDS Sequence Detection System
  • the increase in the amount of fluorescence is measured during each cycle of PCR and reflects the increasing amount of RT-PCR product. Specifically, quantification is based on the threshold cycle, where the amplification plot crosses a defined fluorescence threshold.
  • Comparison of the threshold cycles of the sample with a known standard provides a highly sensitive measure of relative template concentration in different samples (ABI User Bulletin #2 December 11, 1997).
  • the data is analyzed using the ABI SDS program version 1.7.
  • the relative template concentration can be converted to RNA copy numbers by employing a standard curve of HCV RNA standards with known copy number (ABI User Bulletin #2 December 11, 1997).
  • the RT-PCR product was detected using the following labeled probe: 5' FAM-CGAAGCTCCAGGACTGCACGATGCT-TAMRA (SEQ ID NO: 3)
  • FAM Fluorescence reporter dye.
  • TAMRA Quantencher dye.
  • RT reaction is performed at 48 0 C for 30 minutes followed by PCR.
  • Thermal cycler parameters used for the PCR reaction on the ABI Prism 7500 Sequence Detection System are: one cycle at 95 0 C, 10 minutes followed by 40 cycles each of which include one incubation at 95 0 C for 15 seconds and a second incubation for 60 0 C for 1 minute.
  • RT-PCR is performed on the cellular messenger RNA glyceraldehyde-3- phosphate dehydrogenase (GAPDH).
  • GAPDH copy number is very stable in the cell lines used.
  • GAPDH RT-PCR is performed on the same RNA sample from which the HCV copy number is determined.
  • the GAPDH primers and probes are contained in the ABI Pre-Developed TaqMan Assay Kit (catalog no. 4310884E).
  • the ratio of HCV/GAPDH RNA is used to calculate the activity of compounds evaluated for inhibition of HCV RNA replication.
  • HCV replicon RNA levels in Huh-1 l-7cells is determined by comparing the amount of HCV RNA normalized to GAPDH (e.g. the ratio of HCV/GAPDH) in the cells exposed to compound versus cells exposed to the DMSO vehicle (negative control). Specifically, cells are seeded at 4x 10 3 cells/well in a 96 well plate and are incubated either with: 1) media containing 1% DMSO (0% inhibition control), or 2) media/1 %DMSO containing a fixed concentration of compound. 96 well plates as described above are then incubated at 37 0 C for 4 days (EC50 determination). Percent inhibition is defined as:
  • the dose-response curve of the inhibitor is generated by adding compound in serial, three-fold dilutions over three logs to wells starting with the highest concentration of a specific compound at 1.5 uM and ending with the lowest concentration of 0.23 nM. Further dilution series (500 nM to 0.08 nM for example) is performed if the EC50 value is not positioned well on the curve. EC50 is determined with the IDBS Activity Base program "XL Fit" using a 4-paramater, non-linear regression fit (model # 205 in version 4.2.1, build 16) .
  • representative compounds of the present invention are found to have HCV replication inhibitory activity and HCV NS3 protease inhibitory activity. These compounds were also effective in inhibiting HCV NS3 proteases of different HCV genotypes including genotypes 1, 2, 3 and 4.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des composés répondant à la formule I ou II, ou des sels, des esters ou des promédicaments pharmaceutiquement acceptables de ces composés, qui inhibent l'activité de la sérine protéase, particulièrement l'activité de la NS3-NS4A protéase du virus de l'hépatite C (VHC). Par conséquent, les composés de la présente invention interfèrent avec le cycle vital du virus de l'hépatite C et ils se révèlent également utiles en tant qu'agents antiviraux. La présente invention concerne en outre des compositions pharmaceutiques contenant les composés susmentionnés à administrer à un sujet souffrant d'une infection par le VHC. L'invention concerne également des procédés de traitement d'une infection par le VHC chez un sujet grâce à l'administration audit sujet d'une composition pharmaceutique contenant un composé de la présente invention.
PCT/US2007/075588 2006-08-11 2007-08-09 Inhibiteurs triazolyle macrocycliques de la sérine protéase de l'hépatite c WO2008021960A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US50348706A 2006-08-11 2006-08-11
US11/503,487 2006-08-11
US11/835,657 US7662779B2 (en) 2006-08-11 2007-08-08 Triazolyl macrocyclic hepatitis C serine protease inhibitors
US11/835,657 2007-08-08

Publications (2)

Publication Number Publication Date
WO2008021960A2 true WO2008021960A2 (fr) 2008-02-21
WO2008021960A3 WO2008021960A3 (fr) 2008-11-06

Family

ID=39082963

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/075588 WO2008021960A2 (fr) 2006-08-11 2007-08-09 Inhibiteurs triazolyle macrocycliques de la sérine protéase de l'hépatite c

Country Status (1)

Country Link
WO (1) WO2008021960A2 (fr)

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009117594A1 (fr) * 2008-03-20 2009-09-24 Enanta Pharmaceuticals, Inc. Composés macrocycliques fluorés en tant qu'inhibiteurs du virus de l'hépatite c
WO2009140500A1 (fr) * 2008-05-15 2009-11-19 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c
US7781474B2 (en) 2006-07-05 2010-08-24 Intermune, Inc. Inhibitors of hepatitis C virus replication
WO2011017389A1 (fr) 2009-08-05 2011-02-10 Idenix Pharmaceuticals, Inc. Inhibiteurs macrocycliques de la sérine protéase macrocyclique utiles contre les infections virales, en particulier le virus de l’hépatite c
WO2011075615A1 (fr) 2009-12-18 2011-06-23 Idenix Pharmaceuticals, Inc. Inhibiteurs du virus de l'hépatite c à base de 5,5-arylène ou hétéroarylène condensé
US8030307B2 (en) 2007-11-29 2011-10-04 Enanta Pharmaceuticals, Inc. Bicyclic, C5-substituted proline derivatives as inhibitors of the hepatitis C virus NS3 protease
US8119592B2 (en) 2005-10-11 2012-02-21 Intermune, Inc. Compounds and methods for inhibiting hepatitis C viral replication
US8232246B2 (en) 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
WO2012109398A1 (fr) 2011-02-10 2012-08-16 Idenix Pharmaceuticals, Inc. Inhibiteurs macrocycliques de sérine protéase, compositions pharmaceutiques les contenant et leur utilisation pour le traitement des infections par le vhc
US8263549B2 (en) 2007-11-29 2012-09-11 Enanta Pharmaceuticals, Inc. C5-substituted, proline-derived, macrocyclic hepatitis C serine protease inhibitors
WO2012135581A1 (fr) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Procédés pour traiter une infection par virus de l'hépatite c pharmacorésistant par un inhibiteur de virus de l'hépatite c consistant en arylènes ou hétéroarylènes fusionnés en 5,5
US8420596B2 (en) 2008-09-11 2013-04-16 Abbott Laboratories Macrocyclic hepatitis C serine protease inhibitors
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8877929B2 (en) 2008-09-04 2014-11-04 Bristol-Myers Squibb Company Process for synthesizing substituted isoquinolines
US8889871B2 (en) 2002-05-20 2014-11-18 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8937041B2 (en) 2010-12-30 2015-01-20 Abbvie, Inc. Macrocyclic hepatitis C serine protease inhibitors
US8951964B2 (en) 2010-12-30 2015-02-10 Abbvie Inc. Phenanthridine macrocyclic hepatitis C serine protease inhibitors
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2015042375A1 (fr) 2013-09-20 2015-03-26 Idenix Pharmaceuticals, Inc. Inhibiteurs du virus de l'hépatite c
US8993595B2 (en) 2009-04-08 2015-03-31 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
EP2899207A1 (fr) 2014-01-28 2015-07-29 Amikana.Biologics Nouveau procédé pour tester l'inhibition de la protéase du HCV
WO2015134560A1 (fr) 2014-03-05 2015-09-11 Idenix Pharmaceuticals, Inc. Formes solides d'un composé inhibiteur des virus de la famille des flaviviridae et sels de celui-ci
WO2015134561A1 (fr) 2014-03-05 2015-09-11 Idenix Pharmaceuticals, Inc. Compositions pharmaceutiques comprenant un inhibiteur de flaviviridae hétéroarylène fusionné en 5,5 et son utilisation pour le traitement ou la prévention d'une infection par les flaviviridae
US9334279B2 (en) 2012-11-02 2016-05-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9333204B2 (en) 2014-01-03 2016-05-10 Abbvie Inc. Solid antiviral dosage forms
US9409943B2 (en) 2012-11-05 2016-08-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9499550B2 (en) 2012-10-19 2016-11-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9580463B2 (en) 2013-03-07 2017-02-28 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9598433B2 (en) 2012-11-02 2017-03-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050153877A1 (en) * 2003-02-07 2005-07-14 Zhenwei Miao Macrocyclic hepatitis C serine protease inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050153877A1 (en) * 2003-02-07 2005-07-14 Zhenwei Miao Macrocyclic hepatitis C serine protease inhibitors

Cited By (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8889871B2 (en) 2002-05-20 2014-11-18 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9636375B2 (en) 2002-05-20 2017-05-02 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8119592B2 (en) 2005-10-11 2012-02-21 Intermune, Inc. Compounds and methods for inhibiting hepatitis C viral replication
US7781474B2 (en) 2006-07-05 2010-08-24 Intermune, Inc. Inhibitors of hepatitis C virus replication
US8030307B2 (en) 2007-11-29 2011-10-04 Enanta Pharmaceuticals, Inc. Bicyclic, C5-substituted proline derivatives as inhibitors of the hepatitis C virus NS3 protease
US8263549B2 (en) 2007-11-29 2012-09-11 Enanta Pharmaceuticals, Inc. C5-substituted, proline-derived, macrocyclic hepatitis C serine protease inhibitors
WO2009117594A1 (fr) * 2008-03-20 2009-09-24 Enanta Pharmaceuticals, Inc. Composés macrocycliques fluorés en tant qu'inhibiteurs du virus de l'hépatite c
US8372802B2 (en) 2008-03-20 2013-02-12 Enanta Pharmaceuticals, Inc. Fluorinated macrocyclic compounds as hepatitis C virus inhibitors
WO2009140500A1 (fr) * 2008-05-15 2009-11-19 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c
CN102099359A (zh) * 2008-05-15 2011-06-15 百时美施贵宝公司 丙型肝炎病毒抑制剂
US8877929B2 (en) 2008-09-04 2014-11-04 Bristol-Myers Squibb Company Process for synthesizing substituted isoquinolines
US9309279B2 (en) 2008-09-11 2016-04-12 Abbvie Inc. Macrocyclic hepatitis C serine protease inhibitors
US8420596B2 (en) 2008-09-11 2013-04-16 Abbott Laboratories Macrocyclic hepatitis C serine protease inhibitors
US8642538B2 (en) 2008-09-11 2014-02-04 Abbvie, Inc. Macrocyclic hepatitis C serine protease inhibitors
US8993595B2 (en) 2009-04-08 2015-03-31 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
US8232246B2 (en) 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
WO2011017389A1 (fr) 2009-08-05 2011-02-10 Idenix Pharmaceuticals, Inc. Inhibiteurs macrocycliques de la sérine protéase macrocyclique utiles contre les infections virales, en particulier le virus de l’hépatite c
US9284307B2 (en) 2009-08-05 2016-03-15 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors
WO2011075615A1 (fr) 2009-12-18 2011-06-23 Idenix Pharmaceuticals, Inc. Inhibiteurs du virus de l'hépatite c à base de 5,5-arylène ou hétéroarylène condensé
US8937041B2 (en) 2010-12-30 2015-01-20 Abbvie, Inc. Macrocyclic hepatitis C serine protease inhibitors
US8951964B2 (en) 2010-12-30 2015-02-10 Abbvie Inc. Phenanthridine macrocyclic hepatitis C serine protease inhibitors
US9353100B2 (en) 2011-02-10 2016-05-31 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections
WO2012109398A1 (fr) 2011-02-10 2012-08-16 Idenix Pharmaceuticals, Inc. Inhibiteurs macrocycliques de sérine protéase, compositions pharmaceutiques les contenant et leur utilisation pour le traitement des infections par le vhc
WO2012135581A1 (fr) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Procédés pour traiter une infection par virus de l'hépatite c pharmacorésistant par un inhibiteur de virus de l'hépatite c consistant en arylènes ou hétéroarylènes fusionnés en 5,5
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9527885B2 (en) 2011-05-05 2016-12-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201541B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9499550B2 (en) 2012-10-19 2016-11-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9334279B2 (en) 2012-11-02 2016-05-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9598433B2 (en) 2012-11-02 2017-03-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9409943B2 (en) 2012-11-05 2016-08-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9580463B2 (en) 2013-03-07 2017-02-28 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2015042375A1 (fr) 2013-09-20 2015-03-26 Idenix Pharmaceuticals, Inc. Inhibiteurs du virus de l'hépatite c
US9333204B2 (en) 2014-01-03 2016-05-10 Abbvie Inc. Solid antiviral dosage forms
US9744170B2 (en) 2014-01-03 2017-08-29 Abbvie Inc. Solid antiviral dosage forms
US10105365B2 (en) 2014-01-03 2018-10-23 Abbvie Inc. Solid antiviral dosage forms
EP2899207A1 (fr) 2014-01-28 2015-07-29 Amikana.Biologics Nouveau procédé pour tester l'inhibition de la protéase du HCV
WO2015134561A1 (fr) 2014-03-05 2015-09-11 Idenix Pharmaceuticals, Inc. Compositions pharmaceutiques comprenant un inhibiteur de flaviviridae hétéroarylène fusionné en 5,5 et son utilisation pour le traitement ou la prévention d'une infection par les flaviviridae
WO2015134560A1 (fr) 2014-03-05 2015-09-11 Idenix Pharmaceuticals, Inc. Formes solides d'un composé inhibiteur des virus de la famille des flaviviridae et sels de celui-ci

Also Published As

Publication number Publication date
WO2008021960A3 (fr) 2008-11-06

Similar Documents

Publication Publication Date Title
US7662779B2 (en) Triazolyl macrocyclic hepatitis C serine protease inhibitors
WO2008021960A2 (fr) Inhibiteurs triazolyle macrocycliques de la sérine protéase de l'hépatite c
US8785377B2 (en) Tetrazolyl macrocyclic hepatitis C serine protease inhibitors
EP2219453B1 (fr) Composes contenant de la quinoxaline en tant qu'inhibiteurs du virus de l'hepatite c
WO2008021871A2 (fr) Inhibiteurs triazolyle acyclique de la sérine protéase de l'hépatite c
EP2618831B1 (fr) Inhibiteurs macroccliques de la sérine protéase du vhc dérivés de la proline
WO2008021733A2 (fr) Inhibiteurs acycliques tétrazolylés de la sérine protéase de l'hépaptite c
WO2008022006A2 (fr) Inhibiteurs de protéase du virus de l'hépatite c arylalcoxyle
US20090035271A1 (en) Tetrazolyl macrocyclic hepatitis c serine protease inhibitors
WO2008021956A2 (fr) Inhibiteurs d'acylamino-hétéroaryle de la protéase du virus de l'hépatite c
WO2008019303A2 (fr) Inhibiteurs de sérine protéases de l'hépatite c macrocycliques de type pyridazinonyle
WO2009079353A1 (fr) Inhibiteurs macrocycliques contenant du triazole des protéases à sérine du vhc
EP2219454A1 (fr) Inhibiteurs macrocycliques à radical tétrazolyle de la sérine protéase du virus de l'hépatite c
WO2009070692A1 (fr) Inhibiteurs de sérine protéase de l'hépatite c macrocycliques, dérivés de la proline, substitués en c5
EP2268619A1 (fr) Composés macrocycliques fluorés en tant qu'inhibiteurs du virus de l'hépatite c
WO2008134398A1 (fr) Inhibiteurs oximyle dipeptides de protéase de l'hépatite c
WO2008134395A1 (fr) Inhibiteurs macrocycliques azapeptidiques des protéases à sérine du virus de l'hépatite c
WO2009076166A2 (fr) Inhibiteurs oximyles de la sérine protéase de vhc
WO2009085978A1 (fr) Inhibiteurs de protéase de sérine de virus de l'hépatite c d'oxime carbocyclique couronnés
WO2008134397A1 (fr) Inhibiteurs à base d'aza-tripeptide de la sérine protéase de l'hépatite c
WO2009053828A2 (fr) Inhibiteurs p3-hydroxyamino macrocycliques des sérine protéases de l'hépatite c
WO2008002924A2 (fr) Inhibiteurs macrocycliques quinoxalinyliques des protéases à sérine du virus de l'hépatite c
EP2037947A2 (fr) Inhibiteurs oximyles macrocycliques de la protéase de l'hépatite c
WO2009070689A1 (fr) Dérivés de proline bicycliques substitués en c5 en tant qu'inhibiteurs de la protéase ns3 du virus de l'hépatite c
WO2009134987A1 (fr) Composés macrocycliques contenant du difluorométhyle comme inhibiteurs du virus de l’hépatite c

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07840815

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

NENP Non-entry into the national phase in:

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07840815

Country of ref document: EP

Kind code of ref document: A2